Comac Medical Announces Strategic Leadership Transition
December 7, 2023

Landmark Changes Position Company for Continued Growth and Innovation

Sofia, December 6, 2023 – Comac Medical, a leading CRO, is pleased to announce a strategic leadership transition effective January 1, 2024. After more than 25 years at the helm as CEO and founder of Comac Medical, Dr. Milen Vrabevski, MD, will transition to the role of Honorary Chairman of the Supervisory Board. Simultaneously, the company will implement a two-CEO structure, appointing Vladimir Goranov and Dr. Rossitsa Vrabevska, MD, to the shared leadership roles.

Dr. Vrabevski, in his new capacity as Honorary Chairman, will provide strategic guidance based on his extensive industry knowledge and leadership acumen. The planned transition is part of long-term agreed path towards ensuring continuity, stability, and sustainable growth at Comac.

Kristjan Piilmann, Board Member at Comac Medical and Co-founder of majority shareholder Edgecap, commented on the significance of this transition: “The strategic leadership transition at Comac Medical represents a pivotal moment in Comac Medical’s journey. Dr. Milen Vrabevski’s move to Honorary Chairman ensures that Comac Medical continues to benefit from his wealth of experience and industry insights. This transition is not just a passing of the torch but further proof of the deep pool of talent within Comac Medical maintaining the strong momentum of growth and innovation.”

Chris Backes, also Board Member and Co-founder of Edgecap, added: “Comac Medical extends its gratitude to Dr. Milen Vrabevski for his outstanding leadership, and we congratulate Rossitsa and Vladimir on their new roles. This transition underscores our commitment to recognising and nurturing internal talent and providing substantial career growth opportunities within the organisation.”

Vladimir Goranov, with extensive experience in Corporate Finance and Business Development, and Dr. Rossitsa Vrabevska, MD, with a remarkable journey in Clinical Operations, will jointly lead the company into its next phase of growth.

The Supervisory Board, including Honorary Chairman Dr. Milen Vrabevski, Alexander Vrabevski and Edgecap’s Kristjan Piilmann, Christopher Backes and Dr. Günter Schmid will work closely with the Co-CEOs to achieve Comac’s ambitious goals.

About Comac Medical:

Comac Medical, established in 1997 in Sofia, Bulgaria, is one of the largest full-service clinical research organisations (CRO) in South-Eastern Europe, present in more than 30 countries, providing a comprehensive range of early to late-phase drug development services to the global pharmaceutical and biotech industries across a variety of therapeutic areas with a differentiated expertise and track record for indications within oncology, dermatology, gastroenterology, and respiratory diseases.

The Company has a global customer base consisting of emerging biotech and established pharmaceutical companies, offering full outsourced clinical trial support across the entire clinical development timeline. Comac Medical’s FDA and EMA-inspected Clinical Research Unit (CRU) for Phase I, Bioavailability and Bioequivalence studies has 18 years of experience in early phase clinical research and counting over 260 completed clinical trials to date. The facility is the largest in the region and comprises 42 beds, an on-site pharmacy as well as a clinical and bioanalytical laboratory.

For further information, please contact: marketing@comac-medical.com